Elan migraine agent clears FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA approves Elan's 5-HT receptor agonist Frova (frovatriptan succinate) Nov. 8 for acute treatment of migraine, with or without aura, in adults. Launch of the agent, previously called both Miguard and Frovelan, is awaiting the completion of a co-marketing agreement, which is anticipated to be in place by the end of the year